30 results about "Non diabetic" patented technology

The invention relates to a molecular model for auxiliary diagnosis of diabetic nephropathy based on proteomics detection of serum specimens of patients with diabetic nephropathy and non-diabetic nephropathy as well as a construction method and application of the molecular model, which can effectively screen out biomarkers for auxiliary diagnosis model construction and combine with important clinical variables to construct a clinical auxiliary diagnosis model. According to the technical scheme, the molecular model is formed by combining proteins MTTP, TNNI1 and ANGPTL8, the MTTP ratio of diabetic nephropathy patients to non-diabetic kidney disease patients is 8-12.5, the TNNI1 ratio is 7-15, and the ANGPTL8 ratio is 8-14, the protein composition in a sample is detected through a high-throughput mass spectrum means, and the molecular model has the advantages that the molecular model is simple in structure, convenient to operate and high in sensitivity, and the detection accuracy is high. The difference of a diabetic nephropathy patient group and a non-diabetic nephropathy group in the proteomics level is compared, the biomarker for auxiliary diagnosis model construction is screened out, and a new scheme is provided for auxiliary diagnosis of diabetic nephropathy.

The invention discloses a biomarker of type 2 diabetes mellitus and application of the biomarker. The invention provides a group of new biomarkers and therapeutic targets, namely a combination of one or more of ACTN4, AHNAK, ATF4, ATP1A1, B2M, CYBA, GNB2, HES1, PRNP, TMBIM6, TSPAN13, VMP1 and YWHAE for the type 2 diabetes, by analyzing the expression level of the biomarkers, patients with the type 2 diabetes and non-diabetes can be effectively distinguished, a new scheme and way are provided for diagnosis and treatment of the type 2 diabetes, and the application of the biomarkers and the therapeutic targets is broad. The important clinical application value is realized.

The present application belongs to the technical field of artificial intelligence prediction of glucose-metabolism-related diseases, and relates to a method for constructing a glucose-metabolism-related disease prediction model, a method for constructing a non-diabetic subtyping model, and a method for predicating postprandial blood glucose. In the present application, large-scale unlabeled dynamic blood glucose concentration data is used to construct a pre-trained model, and the pre-trained model is fine-tuned on the basis of clinical diagnosis and clinical physiological data, thereby realizing the prediction of glucose-metabolism-related diseases. Secondly, in the present application, dynamic blood glucose feature data is captured on the basis of large-scale CGM data, and non-diabetic dynamic blood glucose distribution data is obtained by means of clustering, thereby realizing the prediction of non-diabetic subtypes of individuals by using individual CGM data and the non-diabetic dynamic blood glucose distribution data. Furthermore, in the present application, individual dynamic blood glucose data obtained by means of continuous glucose monitoring is encoded and embedded into a latent space by means of the pre-trained model to obtain low-dimensional dynamic blood glucose feature data, such that predicted postprandial blood glucose corresponding to dietary structure information can be obtained on the basis of preprandial immediate blood glucose data and the dietary structure information.

The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and / or non-diabetic kidney disease (NDKD).

A method for detecting and treating Type II Diabetes includes the use of hsa_piR_020485, a PIWI-interacting RNA isolated from urinary extracellular vesicles (ECVs), as a biomarker for the diagnosis and treatment of Type 2 diabetes mellitus (T2DM). The method is non-invasive, utilizing the differential expression of hsa_piR_020485 in diabetic versus non-diabetic subjects to identify subjects in need of treatment for T2DM. The method includes obtaining a urine sample from a subject, isolating urinary ECVs from the urine sample, extracting total RNA from the isolated urinary ECVs, quantifying hsa_piR_020485 levels from the total RNA, determining if the hsa_piR_020485 expression level exceeds a threshold, and administering one or more T2DM treatments.

The present invention relates to methods and compositions for preventing type I diabetes. In one aspect, provided herein is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D) comprising: providing a non-diabetic subject at risk of T1D; determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4 +, and / or (3) is not HLA-DR3 +; and administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.

The present disclosure provides at least one entity selected from a compound of Formula I, a tautomer thereof, a deuterated derivative of the compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the entity, and methods of use thereof, including use in the treatment of APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (TID), comprising: providing a non-diabetic subject who is at risk for TID; determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4+, and / or (3) is not HLA-DR3+; and administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.

The present disclosure provides at least one compound, tautomer, deuterated derivative, or pharma- ceutically acceptable salt selected from compounds of formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma- ceutically acceptable salts of any of the foregoing, compositions comprising them, and methods of using them, including use in the treatment of APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

Chronic wounds are characterized by a persistent, overinflamed environment which hinders the progression of regenerative wound closure. Such chronic wounds are particularly common in diabetic patients, typically requiring distal limb amputation, but also occur in non-diabetic elderly patients. HoxA3 is a member of a somatotype modeling and main regulatory transcription factor homologous frame family, and when the HoxA3 is locally applied as a plasmid wrapped in hydrogel, it has been proved that wound closure of diabetic mice can be accelerated through inducible expression of HoxA3. We now provide an independent repetition of these basis in vivo diabetes wound closure studies, and extend it through minimum dose threshold estimation. Furthermore, the natural healing speeds of the wounds of the elderly non-diabetic mouse and the young diabetic mouse are observed to be similar, which provides power for testing local HoxA3 plasmids in the elderly non-diabetic mouse, and the wound healing is observed to be accelerated again. In these short-term studies, we do not observe any serious adverse reaction with naked eyes or through local histology. The local HoxA3 is an attractive transformation candidate target of a chronic wound whether the local HoxA3 is used as a plasmid or a future alternative form.

The invention discloses a diabetic nephropathy prediction system and prediction device based on a mixed index, and belongs to the technical field of computer systems based on a specific calculation model, the system comprises an acquisition module, a weighting module and a prediction module, the acquisition module is used for acquiring clinical characteristics and retinal vascular geometric parameters of a patient; the weighting module is used for constructing a mixing index through the geometric parameters of the retinal vessels based on a weighted quantile regression model; and the prediction module is used for predicting the clinical features and the mixed indexes based on a prediction model, and predicting the clinical features and the mixed indexes as diabetic nephropathy or non-diabetic nephropathy. A weighted quantile regression model is adopted to calculate a mixing effect, differences and internal correlation among individuals are fully considered, and geometric parameters of the retinal vessels are effectively integrated; therefore, the prediction model can identify the diabetic nephropathy more accurately, thereby providing earlier intervention opportunities.

Renal biopsy is a gold standard for determining pathological diagnosis, however, consensus about renal biopsy indications of patients with type 2 diabetes mellitus complicated with chronic kidney disease is still difficult to achieve. The invention provides a kidney biopsy decision model construction method for patients with diabetes mellitus complicated with nephropathy, and aims to guide clinicians to make kidney biopsy decisions for patients with type 2 diabetes mellitus complicated with chronic kidney diseases by using multi-center and large-sample real-world hospitalized patient data. In order to solve the clinical requirement, a non-diabetic nephropathy risk prediction model is constructed, evaluated and verified on the basis of a machine learning algorithm in people who suffer from type 2 diabetes combined with chronic kidney diseases and receive renal biopsy, so that clinicians are assisted in identifying high-risk groups of non-diabetic nephropathy and guiding renal biopsy decisions; a non-diabetic nephropathy risk threshold value is provided, and non-diabetic nephropathy risk layering is carried out on the whole group with the type 2 diabetes mellitus and the chronic kidney disease on the basis of the threshold value.

The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

The present disclosure relates to methods for treating or preventing obesity and other metabolic disorders in diabetic and non-diabetic subjects using combination therapy comprising a therapeutically effective dose of an antagonistic antigen binding molecule that specifically binds to the human glucagon receptor (GCGR) co-administered with a therapeutically effective low dose of glucagon like peptide- 1 receptor (GLP-1 R) agonist peptide approved for treating T2DM or using a bifunctional fusion molecule comprising a glucagon like peptide- 1 receptor (GLP-1 R) agonist peptide fused directly to an antagonistic antigen binding molecule that specifically binds to the human glucagon receptor (GCGR).

The present application belongs to the technical field of artificial intelligence prediction of glucose-metabolism-related diseases, and relates to a method for constructing a glucose-metabolism-related disease prediction model, a method for constructing a non-diabetic subtyping model, and a method for predicating postprandial blood glucose. In the present application, large-scale unlabeled dynamic blood glucose concentration data is used to construct a pre-trained model, and the pre-trained model is fine-tuned on the basis of clinical diagnosis and clinical physiological data, thereby realizing the prediction of glucose-metabolism-related diseases. Secondly, in the present application, dynamic blood glucose feature data is captured on the basis of large-scale CGM data, and non-diabetic dynamic blood glucose distribution data is obtained by means of clustering, thereby realizing the prediction of non-diabetic subtypes of individuals by using individual CGM data and the non-diabetic dynamic blood glucose distribution data. Furthermore, in the present application, individual dynamic blood glucose data obtained by means of continuous glucose monitoring is encoded and embedded into a latent space by means of the pre-trained model to obtain low-dimensional dynamic blood glucose feature data, such that predicted postprandial blood glucose corresponding to dietary structure information can be obtained on the basis of preprandial immediate blood glucose data and the dietary structure information.

The invention relates to the technical field of diabetes risk assessment, and discloses a diabetes risk assessment method and system, and the method comprises the steps: collecting user data, obtaining a diabetes diagnosis standard, and carrying out the judgment of a crowd according to the user data and the diabetes diagnosis standard; establishing a life correction model, a saccharification deviation model and a glycosylation accumulation model, and processing the user data to obtain analysis data; when the crowd is judged to be a non-diabetic crowd, establishing a disease assessment model, calculating a basic risk score by the disease assessment model based on a life correction model, auditing and correcting the basic risk score through a disease condition to obtain a glycosylation correction risk score, and mapping the glycosylation correction risk score into a disease risk level; and when the crowd is determined to be the diabetic crowd, establishing a control evaluation model, calculating a basic control risk level by the control evaluation model based on the life correction model and the glycosylation accumulation model, and auditing and correcting the basic control risk level through a control condition to obtain the control risk level.

Chronic wounds are characterized by a persistent hyperinflammatory environment that inhibits progression toward regenerative wound closure. Such chronic wounds are particularly prevalent in diabetic patients, often necessitating distal limb amputation, but they also occur in non-diabetic and elderly patients. Inducible expression of HoxA3, a homeobox family member and master regulatory transcription factor for body patterning, has been shown to promote wound closure in diabetic mice when administered topically as a plasmid encapsulated in a hydrogel. Here, we provide independent reproducibility of basal in vivo studies of diabetic wound closure and further expand on these studies while minimizing the estimated minimum dose threshold. Furthermore, we observed similarities in spontaneous wound healing rates between non-diabetic aged mice and diabetic young mice, which motivated us to test the topical application of HoxA3 plasmids in non-diabetic aged mice, where accelerated wound healing was also observed. In these short studies, no significant adverse effects were observed macroscopically or by local histology. Local administration of HoxA3, either as a plasmid or as a future alternative therapy, is a noteworthy translational option for chronic wounds.

The present disclosure relates to methods for treating or preventing obesity and other metabolic disorders in diabetic and non-diabetic subjects using combination therapy comprising a therapeutically effective dose of an antagonistic antigen binding molecule that specifically binds to the human glucagon receptor (GCGR) co-administered with a therapeutically effective low dose of glucagon like peptide- 1 receptor (GLP-1 R) agonist peptide approved for treating T2DM or using a bifunctional fusion molecule comprising a glucagon like peptide- 1 receptor (GLP-1 R) agonist peptide fused directly to an antagonistic antigen binding molecule that specifically binds to the human glucagon receptor (GCGR).

The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

The present application relates to the technical field of diabetes risk assessment, and discloses a diabetes risk assessment method and system, comprising: collecting user data, obtaining a diabetes diagnosis standard, and performing crowd determination according to the user data and the diabetes diagnosis standard; establishing a life correction model, a glycation deviation model and a glycosylation accumulation model, processing the user data to obtain analysis data; when the crowd determination is a non-diabetes crowd, establishing an onset evaluation model, the onset evaluation model calculating a basic risk score based on the life correction model, correcting the basic risk score through onset condition auditing to obtain a glycosylation corrected risk score, and mapping the glycosylation corrected risk score to an onset risk grade; when the crowd determination is a diabetes crowd, establishing a control evaluation model, the control evaluation model calculating a basic control risk grade based on the life correction model and the glycosylation accumulation model, and correcting the basic control risk grade through control condition auditing to obtain a control risk grade.

The invention relates to application of a specific inhibitor BAY-876 targeting glucose transporter 1 in prevention and treatment of hypoglycemia. The hypoglycemia is at least one of diabetic hypoglycemia, non-diabetic hypoglycemia and recurrent hypoglycemia. The invention also provides a medicine for preventing and / or treating at least one disease of diabetic hypoglycemia, non-diabetic hypoglycemia and recurrent hypoglycemia. Meanwhile, the invention further provides application of the BAY-876 in preparation of drugs capable of improving the fasting glucagon level of a diabetic individual and / or a non-diabetic individual in vivo and / or maintaining fasting blood glucose stability in vivo and / or improving diabetic hypoglycemia and non-diabetic hypoglycemia in vivo. The invention also relates to application of the medicine or the reagent for reverse regulation of at least one disease in recurrent hypoglycemia. In conclusion, the invention provides a new means for developing medicines for preventing and / or treating at least one disease of diabetic hypoglycemia, non-diabetic hypoglycemia and recurrent hypoglycemia.

The invention belongs to the technical field of medical data processing, and discloses a collaborative generation method and system for a diabetes risk value assessment and intervention scheme, and the method comprises the steps: obtaining the five-mode data of the physiology, life behavior, heredity, environment and medical service utilization of a non-diabetic population; adopting a space-time attention mechanism to mine dynamic association between modes to generate dynamic interaction features; based on a preset crowd / scene dimension, utilizing the contribution degree and the attention weight to adaptively screen out a simplified feature set; a multi-task collaborative integrated prediction framework with diabetes attack risk prediction as a main task and intervention response prediction as an auxiliary task is constructed, a prediction result is weighted based on a three-dimensional dynamic weight calculated based on modal contribution degree, feature importance and task loss, and an attack risk value and an optimal intervention scheme are output. According to the invention, through dynamic mining of multi-modal data interaction, adaptive screening of features and linkage prediction of risk and intervention schemes, the prediction accuracy is improved.

The present disclosure provides at least one compound selected from the group consisting of compounds of Formula I, tautomers thereof, deuterated derivatives of these compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, tautomers, deuterated derivatives, or pharmaceutically acceptable salts, compositions including the same, and methods of using the same, in particular, the present invention relates to the use thereof, including the use thereof in the treatment of APOL1 mediated diseases, including pancreatic cancer, focal segmental glomerular sclerosis (FSGS), and / or non-diabetic kidney disease (NDKD). # imgabs0 #

The present disclosure provides at least one compound, tautomer, deuterated derivative or pharmaceutically acceptable salt selected from the group consisting of compounds of Formula I, tautomers thereof, deuterated derivatives of these compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing; compositions including the same; the present invention relates to novel compounds, and methods of using the same, including the use of treating APOL1 mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic nephropathy (NDKD).

To provide a method for preventing or delaying the onset of clinical type 1 diabetes (T1D).SOLUTION: Providing a non-diabetic subject at risk of T1D, administering to the non-diabetic subject a prophylactically effective amount of anti- CD3 antibodies, and prior to or subsequent to the administering step, determining that the non-diabetic subject has greater than about 5% to greater than about 10% TIGIT + T1D + CD3 + T cells among total KLRG1 + T cells, indicating successful prevention or delay of the onset of clinical CD8.SELECTED DRAWING: None

The present disclosure relates to chemical moieties which, when bonded to pharmacophores, cause the pharmacophores to undergo first pass metabolism. By undergoing first pass metabolism, a pharmacophore may be made less bioavailable. Such compounds and related pharmaceutical compositions may be used for targeted treatment of diabetic and non-diabetic gastrointestinal disorders, with minimal systemic circulation beyond the gastrointestinal tract.

The invention relates to the field of biological medicine, and discloses application of GLP-1RA in preparation of a medicine for improving podocyte damage and / or reducing urine protein. According to the application, an FSGS mouse model induced by adriamycin is used, the model has no hyperglycemia phenotype, the blood sugar reducing effect of liraglutide can be excluded, the protection effect of liraglutide on podocytes independent of blood sugar reducing can be better verified, and meanwhile, in-vivo and in-vitro GLP1R overexpression models are constructed to observe the effect. Results show that liraglutide can significantly reduce the level of doxorubicin-induced urine protein and improve podocyte injury, and liraglutide may play a positive role in non-diabetic nephropathy, and provides a new idea for comprehensive treatment of kidney diseases.